EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ALX Oncology Holdings's Enterprise Value is $653.05 Mil.
ALX Oncology Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-131.64 Mil. Therefore, ALX Oncology Holdings's EV-to-FCF for today is -4.96.
The historical rank and industry rank for ALX Oncology Holdings's EV-to-FCF or its related term are showing as below:
ALXO'
s EV-to-FCF Range Over the Past 10 Years
Min: -86.37 Med: -4.9 Max: 7.56
Current: -4.96
During the past 6 years, the highest EV-to-FCF of ALX Oncology Holdings was 7.56. The lowest was -86.37. And the median was -4.90.
ALXO's EV-to-FCF is ranked worse than 100% of 390
companies
in the Biotechnology industry
Industry Median: 6.365
vs ALXO: -4.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ALX Oncology Holdings's EV-to-FCF
For the Biotechnology subindustry, ALX Oncology Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ALX Oncology Holdings's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's EV-to-FCF falls into.
ALX Oncology Holdings's current Enterprise Value is $653.05 Mil.
ALX Oncology Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-131.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ALX Oncology Holdings's PE Ratio for today is calculated as:
ALX Oncology Holdings's share price for today is $16.21.
ALX Oncology Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ALX Oncology Holdings EV-to-FCF Related Terms
Thank you for viewing the detailed overview of ALX Oncology Holdings's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
ALX Oncology Holdings (ALX Oncology Holdings) Business Description
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALXO has been successfully added to your 